GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001049822 | Liver | HCC | proteasomal protein catabolic process | 351/7958 | 490/18723 | 6.92e-40 | 1.46e-36 | 351 |
GO:004316122 | Liver | HCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 299/7958 | 412/18723 | 7.82e-36 | 8.27e-33 | 299 |
GO:000989622 | Liver | HCC | positive regulation of catabolic process | 335/7958 | 492/18723 | 3.83e-31 | 1.87e-28 | 335 |
GO:003133122 | Liver | HCC | positive regulation of cellular catabolic process | 295/7958 | 427/18723 | 3.20e-29 | 1.45e-26 | 295 |
GO:004217622 | Liver | HCC | regulation of protein catabolic process | 267/7958 | 391/18723 | 2.45e-25 | 7.38e-23 | 267 |
GO:190336222 | Liver | HCC | regulation of cellular protein catabolic process | 182/7958 | 255/18723 | 5.91e-21 | 8.52e-19 | 182 |
GO:000697922 | Liver | HCC | response to oxidative stress | 281/7958 | 446/18723 | 9.75e-19 | 1.24e-16 | 281 |
GO:004573222 | Liver | HCC | positive regulation of protein catabolic process | 163/7958 | 231/18723 | 4.00e-18 | 4.69e-16 | 163 |
GO:190305022 | Liver | HCC | regulation of proteolysis involved in cellular protein catabolic process | 157/7958 | 221/18723 | 5.93e-18 | 6.83e-16 | 157 |
GO:190332022 | Liver | HCC | regulation of protein modification by small protein conjugation or removal | 167/7958 | 242/18723 | 4.99e-17 | 4.72e-15 | 167 |
GO:006113622 | Liver | HCC | regulation of proteasomal protein catabolic process | 134/7958 | 187/18723 | 5.03e-16 | 4.09e-14 | 134 |
GO:004325422 | Liver | HCC | regulation of protein-containing complex assembly | 264/7958 | 428/18723 | 5.47e-16 | 4.39e-14 | 264 |
GO:006219722 | Liver | HCC | cellular response to chemical stress | 216/7958 | 337/18723 | 6.86e-16 | 5.44e-14 | 216 |
GO:200123322 | Liver | HCC | regulation of apoptotic signaling pathway | 226/7958 | 356/18723 | 7.26e-16 | 5.68e-14 | 226 |
GO:190336422 | Liver | HCC | positive regulation of cellular protein catabolic process | 115/7958 | 155/18723 | 9.30e-16 | 7.19e-14 | 115 |
GO:200005822 | Liver | HCC | regulation of ubiquitin-dependent protein catabolic process | 120/7958 | 164/18723 | 1.31e-15 | 9.74e-14 | 120 |
GO:004586222 | Liver | HCC | positive regulation of proteolysis | 232/7958 | 372/18723 | 5.66e-15 | 3.98e-13 | 232 |
GO:003243422 | Liver | HCC | regulation of proteasomal ubiquitin-dependent protein catabolic process | 100/7958 | 134/18723 | 3.67e-14 | 2.32e-12 | 100 |
GO:003139622 | Liver | HCC | regulation of protein ubiquitination | 142/7958 | 210/18723 | 1.39e-13 | 7.81e-12 | 142 |
GO:003459922 | Liver | HCC | cellular response to oxidative stress | 183/7958 | 288/18723 | 3.65e-13 | 1.93e-11 | 183 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05142 | Liver | HCC | Chagas disease | 61/4020 | 102/8465 | 8.04e-03 | 2.17e-02 | 1.21e-02 | 61 |
hsa049262 | Liver | HCC | Relaxin signaling pathway | 75/4020 | 129/8465 | 9.33e-03 | 2.46e-02 | 1.37e-02 | 75 |
hsa01522 | Liver | HCC | Endocrine resistance | 58/4020 | 98/8465 | 1.28e-02 | 3.19e-02 | 1.78e-02 | 58 |
hsa04917 | Liver | HCC | Prolactin signaling pathway | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
hsa051612 | Liver | HCC | Hepatitis B | 91/4020 | 162/8465 | 1.56e-02 | 3.76e-02 | 2.09e-02 | 91 |
hsa0541742 | Liver | HCC | Lipid and atherosclerosis | 118/4020 | 215/8465 | 1.66e-02 | 3.92e-02 | 2.18e-02 | 118 |
hsa052316 | Liver | HCC | Choline metabolism in cancer | 57/4020 | 98/8465 | 2.14e-02 | 4.90e-02 | 2.72e-02 | 57 |
hsa0414132 | Liver | HCC | Protein processing in endoplasmic reticulum | 146/4020 | 174/8465 | 7.34e-24 | 2.46e-21 | 1.37e-21 | 146 |
hsa0501232 | Liver | HCC | Parkinson disease | 198/4020 | 266/8465 | 9.40e-20 | 1.58e-17 | 8.76e-18 | 198 |
hsa0501632 | Liver | HCC | Huntington disease | 219/4020 | 306/8465 | 3.06e-18 | 3.42e-16 | 1.90e-16 | 219 |
hsa0520852 | Liver | HCC | Chemical carcinogenesis - reactive oxygen species | 167/4020 | 223/8465 | 2.85e-17 | 1.91e-15 | 1.06e-15 | 167 |
hsa0493252 | Liver | HCC | Non-alcoholic fatty liver disease | 124/4020 | 155/8465 | 4.54e-17 | 2.54e-15 | 1.41e-15 | 124 |
hsa0502032 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
hsa0541532 | Liver | HCC | Diabetic cardiomyopathy | 151/4020 | 203/8465 | 2.72e-15 | 1.01e-13 | 5.63e-14 | 151 |
hsa0513252 | Liver | HCC | Salmonella infection | 178/4020 | 249/8465 | 5.90e-15 | 1.98e-13 | 1.10e-13 | 178 |
hsa0517152 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa0501032 | Liver | HCC | Alzheimer disease | 254/4020 | 384/8465 | 3.75e-14 | 8.97e-13 | 4.99e-13 | 254 |
hsa0502232 | Liver | HCC | Pathways of neurodegeneration - multiple diseases | 298/4020 | 476/8465 | 6.59e-12 | 1.30e-10 | 7.22e-11 | 298 |
hsa0414031 | Liver | HCC | Autophagy - animal | 99/4020 | 141/8465 | 3.08e-08 | 4.70e-07 | 2.61e-07 | 99 |
hsa0521032 | Liver | HCC | Colorectal cancer | 65/4020 | 86/8465 | 8.85e-08 | 1.23e-06 | 6.87e-07 | 65 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAPK9 | SNV | Missense_Mutation | novel | c.523A>T | p.Thr175Ser | p.T175S | P45984 | protein_coding | tolerated(0.5) | benign(0.001) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAPK9 | insertion | In_Frame_Ins | novel | c.944_945insATCTATTCTGTGCCATTGGCTTTGGTTACATCC | p.Ala315_Leu316insSerIleLeuCysHisTrpLeuTrpLeuHisPro | p.A315_L316insSILCHWLWLHP | P45984 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAPK9 | insertion | In_Frame_Ins | novel | c.521_522insTGTTCACAGGCACTTCTTGTTTCTGGTTTTTTGTTT | p.Arg174_Thr175insValHisArgHisPheLeuPheLeuValPheCysLeu | p.R174_T175insVHRHFLFLVFCL | P45984 | protein_coding | | | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAPK9 | SNV | Missense_Mutation | | c.196N>T | p.His66Tyr | p.H66Y | P45984 | protein_coding | deleterious(0.02) | possibly_damaging(0.672) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MAPK9 | SNV | Missense_Mutation | | c.877N>G | p.Gln293Glu | p.Q293E | P45984 | protein_coding | tolerated(0.22) | benign(0.103) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAPK9 | SNV | Missense_Mutation | | c.373N>T | p.His125Tyr | p.H125Y | P45984 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MAPK9 | SNV | Missense_Mutation | novel | c.1190C>T | p.Ser397Leu | p.S397L | P45984 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.879) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAPK9 | SNV | Missense_Mutation | novel | c.715G>A | p.Glu239Lys | p.E239K | P45984 | protein_coding | tolerated(0.33) | benign(0.152) | TCGA-AA-3930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | PD |
MAPK9 | SNV | Missense_Mutation | novel | c.752N>C | p.Lys251Thr | p.K251T | P45984 | protein_coding | deleterious(0) | possibly_damaging(0.897) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAPK9 | SNV | Missense_Mutation | | c.1078G>C | p.Val360Leu | p.V360L | P45984 | protein_coding | deleterious(0.04) | benign(0.011) | TCGA-AA-A02F-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | PR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5601 | MAPK9 | KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | CAMPTOTHECIN | CAMPTOTHECIN | 10839298 |
5601 | MAPK9 | KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | PMID25991433-Compound-P4 | | |
5601 | MAPK9 | KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | inhibitor | 178102618 | | |
5601 | MAPK9 | KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | AG-1879 | CHEMBL406845 | |
5601 | MAPK9 | KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | OSI-632 | OSI-632 | |
5601 | MAPK9 | KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | inhibitor | 178101956 | | |
5601 | MAPK9 | KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | PD-0166285 | PD-0166285 | |
5601 | MAPK9 | KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | SB-220025 | SB-220025 | |
5601 | MAPK9 | KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | PMID25991433-Compound-O3 | | |
5601 | MAPK9 | KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | inhibitor | 223366077 | RGB-286638 | |